ACHN: ACH-1625 Phase-1b Results by Cohort
(Revised—thanks, turtlepower)
Cumulative No. of Mean Log VL Mean Log VL iHub
Cohort Daily Dose Patients Chg*(absolute) Chg*(pbo adj) Reference
600mg BID 1200mg 6,3 3.94 3.72 #msg-44560695
500mg BID 1000mg 6,3 4.25 3.96 #msg-45339022
600mg qD 600mg 6,2 3.81 4.05 #msg-50041722
200mg BID 400mg 6,3 3.86 4.02 #msg-50041722
*Maximum reduction during five days of dosing.
Conclusion: All of the above doses have sufficient efficacy. 600mg qD (or perhaps an even lower qD dose) will presumably be the dose to be carried forward into phase-2 trials.